Compounds > capecitabine
Page last updated: 2024-08-24

capecitabine and Central Nervous System Neoplasm

capecitabine has been researched along with Central Nervous System Neoplasm in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Dodwell, D; Heudtlass, P; Johnston, S; Marshall, H; Murden, G; Oughton, JB; Passant, H; Pottinger, A; Price, C; Rizwanullah, M; Seligmann, JF; Velikova, G; Wright-Hughes, A1
de Stanchina, E; Fleisher, M; Kemeny, MM; Li, BT; Morikawa, A; Norton, L; Patil, S; Pentsova, E; Seidman, AD; Tang, K; Van Poznak, C1
Blackwell, K; Diéras, V; Guardino, E; Huober, J; Krop, IE; Lin, NU; Lu, M; Miles, D; Samant, M; Welslau, M1
Abrey, LE; Deangelis, LM; Ekenel, M; Hormigo, AM; Peak, S1

Trials

4 trial(s) available for capecitabine and Central Nervous System Neoplasm

ArticleYear
Lapatinib plus Capecitabine versus Trastuzumab plus Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer with Central Nervous System Metastases for Patients Currently or Previously Treated with Trastu
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2020, Volume: 32, Issue:10

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Female; Humans; Lapatinib; Middle Aged; Prognosis; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Trastuzumab

2020
Phase I Study of Intermittent High-Dose Lapatinib Alternating with Capecitabine for HER2-Positive Breast Cancer Patients with Central Nervous System Metastases.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 07-01, Volume: 25, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Drug Administration Schedule; Humans; Lapatinib; Middle Aged; Neoplastic Cells, Circulating; Receptor, ErbB-2; Treatment Outcome

2019
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:1

    Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Lapatinib; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Young Adult

2015
Capecitabine therapy of central nervous system metastases from breast cancer.
    Journal of neuro-oncology, 2007, Volume: 85, Issue:2

    Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Carcinoma; Central Nervous System Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Meningeal Neoplasms; Middle Aged; Prodrugs; Retrospective Studies; Treatment Outcome

2007